PMC5329790_01
Computer tomography (CT) scans of lung lesion and brain metastasis before and after icotinib treatment. (A and B) At diagnosis of the metastases (Oct 12, 2013); (C and D) After 16 days of icotinib therapy (Oct 28, 2013), revealing a good response to treatment; (E and F) After 47 days of icotinib treatment (Nov 26, 2013), revealing brain lesion completed resolved.
j_med-2016-0003_fig_001.jpg
PMC5329790_01_j_med-2016-0003_fig_001.jpg
j_med-2016-0003_fig_001
C-D), a significant improvement regarding partial response (PR) was observed, as evidenced by a 37.1% reduction in the size of lesion on average, and a quick absence in brain metastasis after 46 days of treatment (Figs.1 F). Considering the brain tumor had complete remission, we decided to monitor brain tumors by every 2 months using CT scan rather than a brain radiation therapy.
Abdominal computed tomography (CT) imaging of metastatic live lesion lymph node lesions before and after AZD9291 treatment. (A and B) At diagnosis of the metastases after administrating icotinib for 14 months (Dec 23, 2014); (C and D) After 2 months of transcatheter arterial chemoembolization, revealing disease progression (Mar 27, 2015); (E and F) After 20 days of combination treatment of icotinib and AZD9291, revealing a dramatic response (Apr 3, 2015).
j_med-2016-0003_fig_002.jpg
PMC5329790_01_j_med-2016-0003_fig_002.jpg
j_med-2016-0003_fig_002
Unfortunately, on March 24, 2015, a poor clinical response to the TACE was reported, along with new liver metastases (Fig.2 C-D). Three weeks later, we observed a significant reduction in liver lesions and lymph node lesions, and an average shrinkage of 35.1% in target lesion size (Fig.2 E-F).